Characterisation of kidney masses to identify cancer Cancer Renal cancer, malignant neoplasms of urinary tract, benign neoplasms
Conditions
Interventions
After consent and eligibility is confirmed, participants will attend the Royal Free Hospital for the 99mTc Sestamibi SPECT/CT scan. This is likely to take place within 2 weeks of providing consent. Th
Sponsors
University College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult patients >18 years of age and less than 95 years 2. Renal tumour >2 cm identified on cross sectional imaging (CT or MRI) 3. Patients undergoing tumour biopsy, surgery or who have previously had a biopsy and are on active surveillance programmes 4. Capacity to provide informed consent
Exclusion criteria
Exclusion criteria: 1. Females who are pregnant, planning pregnancy or breastfeeding 2. Concurrent and/or recent involvement in other research that is likely to interfere with the intervention within 3 months of study enrolment 3. Multiple comorbidities which would make trial participation difficult (e.g. burden of an additional hospital visit) 4. Allergy to 99m Tc-sestamibi
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity and specificity of the 99mTc-sestamibi SPECT/CT scan to detect cancer reported by the nuclear medicine consultant (results will be matched with the histological tissue diagnosis, either by conventional tumour biopsy or surgery [the reference standard]) at a single timepoint | — |
Secondary
| Measure | Time frame |
|---|---|
| Acceptability of 99mTc Sestamibi SPECT/CT scans in the diagnostic pathway of renal masses measured the Quality of Life questionnaire (EQ5DL) will given at screening (pre-treatment), as part of the first telephone assessment (day 15 + 2 days) and the second telephone assessment (day 28 + 14 days) | — |
Countries
England, United Kingdom
Outcome results
None listed